RepliCel Provides Quarterly Update on First-In-Man Clinical Trials
Is pleased to report that the six-month post injection follow-up period of its TS001-2009 clinical trial is nearing completion.To date, 17 of 19 subjects have had their six-month follow-up visit, during which time subjects had their overall health evaluated. This included subjective and objective assessment of verum and placebo injected sites and digital images were taken of the scalp and injection areas. The digital images will be used to assess any treatment response and any post-injection changes in scalp health compared to baseline and between the two treatment areas. The remaining two patients are scheduled to complete their follow-up visits before the end of March. Four patients will complete 12-month follow-up visits in that same time frame.
To date, no serious adverse events have been reported post injection in any of the 10 men and 9 women participating in the study.

Depression



